menu search

Why altcoins and crypto miner stocks surged on monday

An explosive story about a Bitcoin asset manager turned out to be inaccurate....

October 16, 2023, 7:53 pm

Gold price forecast – key breakout and support levels for october

The October washout in metals and miners is most likely over, and we may be in the beginning stages of ...

October 16, 2023, 6:16 pm

Why riot platforms, hut 8 mining, and terawulf popped on monday

A false report circulated this morning saying that a Bitcoin ETF had been approved. miners responded bu...

October 16, 2023, 3:20 pm

Aclara resources reports discovery of new heavy rare earths deposit at carina module in brazil

Aclara Resources Inc (TSX:ARA, OTC:ARAAF) announced that its initial auger drilling campaign at its Carina Module project in the State of Goiás, Braz...

October 16, 2023, 11:43 am

Troilus gold corp boosts resource base to 13mln ounces

Troilus Gold Corp (TSX:TLG, OTCQX:CHXMF) has released details of an updated resource estimate for the Troilus project in northcentral Quebec, Canada, ...

October 16, 2023, 9:13 am

Gold terra resource drills high-grade gold at con mine option property in northwest territories

Gold Terra Resource Corp (TSX-V:YGT, OTCQX:YGTFF) announced that drill hole GTCM23-055 has intersected the upper portion of the high-grade gold-bearin...

October 16, 2023, 9:01 am

Bitcoin mining in 2022: the year boom turned to bust – forbes

Bitcoin mining’s economics shattered in 2022For bitcoin miners, 2022 was the year that the gold rush ...

October 16, 2023, 8:14 am

Aterian climbs 5% on latest exploration news from morocco

Aterian, the Morocco-focused minerals explorer, jumped 5% on some encouraging samples from its Tata pro...

October 16, 2023, 4:08 am

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm

Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...

October 14, 2023, 8:30 pm


Search within

Pages Search Results: